Study of renal cancers and renal cancer metastases - EGA European Genome-Phenome Archive

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00010001001	Primary renal cell carcinoma (RCC), RCC metastases and cell lines by Illumina 450K	Illumina 450K	62
EGAD00010001564	Primary renal cell carcinoma (RCC) by Affymetrix GeneChip miRNA 4.0	Affymetrix GeneChip miRNA 4.0	56
EGAD00010001589	Primary renal cell carcinoma (RCC) and RCC metastases by Affymetrix GeneChip HTA 2.0	Affymetrix Human Transcriptome Array 2.0	112
EGAD00010002323	GeneChip HTA 2.0 data of primary renal cell carcinoma (RCC) related to Reustle et al, Genome Med 12:2020 32. Preprocessing of microarray data was performed using Robust Multi-array Average (RMA).	GeneChip HTA 2.0	53
EGAD00010002352	GeneChip HTA 2.0 data of primary renal cell carcinoma (RCC) related to Reustle et al., Clin Transl Med 12:2022 e883. Microarrays were normalized individually using the SCAN method from the R package SCAN.UPC (version 2.26.0, R version 3.6.1). Probe sets were summarized on the Entrez GeneID level using the annotation provided by BrainArray (version 23).	GeneChip HTA 2.0	124
EGAD00010002353	GeneChip HTA 2.0 data of primary renal cell carcinoma (RCC) related to Buettner et al, Genome Med 2022. Microarrays were normalized individually using the SCAN method from the R package SCAN.UPC (version 2.26.0, R version 3.6.1). Probe sets were summarized on the Entrez GeneID level using the annotation provided by BrainArray (version 23).	GeneChip HTA 2.0	306
EGAD00010002392	GeneChip HTA 2.0 data of primary renal cell carcinoma (RCC) and RCC metastases related to Guergen et al, Front Oncol 12:2022 889789. Microarrays were normalized individually using the SCAN method from the R package SCAN.UPC (version 2.34.0). Probe sets were summarized on the Entrez GeneID level using the annotation provided by BrainArray (version 25).	GeneChip HTA 2.0	24

Publications	Citations
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E. Sci Rep 6: 2016 29930	28
Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. Schaeffeler E, Büttner F, Reustle A, Klumpp V, Winter S, Rausch S, Fisel P, Hennenlotter J, Kruck S, Stenzl A, Wahrheit J, Sonntag D, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M. Eur Urol Focus 5: 2019 608-618	30
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E. BMC Med 16: 2018 108	11
Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. Reustle A, Fisel P, Renner O, Büttner F, Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, Fend F, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Int J Cancer 143: 2018 3181-3193	32
Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. Kandabarau S, Leiz J, Krohn K, Winter S, Bedke J, Schwab M, Schaeffeler E, Edemir B. Cancers (Basel) 12: 2019 E6	4
Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E. Genome Med 12: 2020 32	31
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Clin Transl Med 12: 2022 e883	18
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. Gürgen D, Becker M, Dahlmann M, Flechsig S, Schaeffeler E, Büttner FA, Schmees C, Bohnert R, Bedke J, Schwab M, Wendler JJ, Schostak M, Jandrig B, Walther W, Hoffmann J. Front Oncol 12: 2022 889789	2
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E. Genome Med 14: 2022 105	18